Pathogenesis of Acute Lymphoblastic Leukemia
Archives of Medical Laboratory Sciences,
Vol. 4 No. 1 (2018),
2 Esfand 2019
https://doi.org/10.22037/amls.v4i1.23075
Abstract
Acute lymphoblastic leukemia (ALL) is a hematological malignant disease characterized by an enhanced self-renewal ability of precursor lymphoid cells whose cell division takes more time than their normal counterparts.
ALL occurs most between 2 to 5 years of age and during the sixth decade of life. There is a strong relationship between the time ALL occurs in children and the genetic abnormalities which are identified by the rate of leukemic concordance between identical twins.
About 90% of ALL cases do not have a clear etiological mechanism. Genetic syndromes, polymorphic variants genes, germline mutations, and some environmental factors are responsible for less than 10% of ALL predisposition but the pathogenesis mechanism of ALL is not identified precisely.
Here we review the recent findings and earlier studies about the pathogenesis of acute lymphoblastic leukemia and its incidence. This article also summarizes the identification of predictive factors for ALL and options available to predict disease recurrence.
- Acute lymphoblastic leukemia
- Genetic abnormalities
- Incidence
- Pathogenesis
How to Cite
References
Cobaleda C, Sánchez‐García I. B‐cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays. 2009;31(6):600-9.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-32.
Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. The Lancet. 2008;371(9617):1030-43.
Zuckerman T, Rowe JM. Pathogenesis and prognostication in acute lymphoblastic leukemia. F1000Prime Rep. 2014;6(59):1-5.
Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-84.
Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer- Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-14.
Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-50.
Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. The lancet oncology. 2010;11(5):429-38.
Hjalgrim LL, Westergaard T, Rostgaard K, Schmiegelow K, Melbye M, Hjalgrim H, et al. Birth weight as a risk factor for childhood leukemia: a meta-analysis of 18 epidemiologic studies. American journal of epidemiology. 2003;158(8):724-35.
Le Jeune C, Thomas X. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Drug design, development and therapy. 2016;10:757.
Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121(15):2517-28.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62(1):10-29.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65(1):5-29.
Stanulla M, Schrappe M, editors. Treatment of childhood acute lymphoblastic leukemia. Seminars in hematology; 2009: Elsevier.
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. Journal of Clinical Oncology. 2012:JCO. 2011.37. 8018.
Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. Journal of clinical oncology. 2011;29(5):532-43.
Hunger SP, Loh ML, Whitlock JA, Winick NJ, Carroll WL, Devidas M, et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatric blood & cancer. 2013;60(6):957-63.
Kaatsch P. Epidemiology of childhood cancer. Cancer treatment reviews. 2010;36(4):277-85.
Rivera‐Luna R, Correa‐González C, Altamirano‐Alvarez E, Sánchez‐Zubieta F, Cárdenas‐Cardós R, Escamilla‐Asian G, et al. Incidence of childhood cancer among Mexican children registered under a public medical insurance program. International Journal of Cancer. 2013;132(7):1646-50.
Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Cortes J, Burger JA, et al. Chemoimmunotherapy with a Modified Hyper- CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood. 2009;114(22):836-.
Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843-50.
Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070-7.
Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014;28(4):973-5.
Salim H, Ariawati K, Suryawan WB, Arimbawa M. Osteoporosis resulting from acute lymphoblastic leukemia in a 7-year-old boy: a case report. Journal of medical case reports. 2014;8(1):1.
Strauss AJ, Su JT, Dalton VMK, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. Journal of Clinical Oncology. 2001;19(12):3066-72.
Kaste S, Jones-Wallace D, Rose S, Boyett J, Lustig R, Rivera G, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia. 2001;15(5):728-34.
Smith OP, Hann IM. Clinical features and therapy of lymphoblastic leukemia. Pediatric Hematology, Third Edition. 2006:450-81.
Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. New England Journal of Medicine. 2006;355(15):1572-82.
Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. Journal of Clinical Oncology. 2009;27(14):2328-38.
Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long-term cause-specific mortality among survivors of childhood cancer. Jama. 2010;304(2):172-9.
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New England Journal of Medicine. 1991;324(12):808-15.
Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(12):2629-36.
de Andrade JM. Limitações para o sucesso do rastreamento do câncer de colo no Brasil. Rev Bras Ginecol Obstet. 2012;14049(34):900.
Loghavi S, Kutok JL, Jorgensen JL. B-acute lymphoblastic leukemia/lymphoblastic lymphoma. American journal of clinical pathology. 2015;144(3):393-410.
Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino J. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with down syndrome. Leukemia. 2016.
Varon R, Reis A, Henze G, Einsiedel HGv, Sperling K, Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer research. 2001;61(9):3570-2.
German J, Bloom D, Passarge E. Bloom's syndrome. V. Surveillance for cancer in affected families. Clinical genetics. 1977;12(3):162-8.
Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. Journal of clinical pathology. 2001;54(7):512-6.
Pui C-H, Relling MV, Downing JR. Acute lymphoblastic leukemia. New England Journal of Medicine. 2004;350(15):1535- 48.
Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-83.
Izraeli S, Vora A, Zwaan CM, Whitlock J. How I treat ALL in Down's syndrome: pathobiology and management. Blood. 2014;123(1):35-40.
Izraeli S. Similar yet different. Blood. 2010;116(7):1019-20.
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. 2009;106(23):9414-8.
Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor–and Down syndrome–associated acute lymphoblastic leukemia. Nature genetics. 2009;41(11):1243-6.
Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006-17.
Olsson L, Johansson B. Ikaros and leukaemia. British journal of haematology. 2015;169(4):479-91.
Asai D, Imamura T, Suenobu Si, Saito A, Hasegawa D, Deguchi T, et al. IKZF1 deletion is associated with a poor outcome in pediatric B‐cell precursor acute lymphoblastic leukemia in Japan. Cancer medicine. 2013;2(3):412-9.
Liberzon E, Avigad S, Stark B, Zilberstein J, Freedman L, Gorfine M, et al. Germ‐line ATM gene alterations are associated with susceptibility to sporadic T‐cell acute lymphoblastic leukemia in children. Genes, Chromosomes and Cancer. 2004;39(2):161-6.
Draper G, Vincent T, Kroll ME, Swanson J. Childhood cancer in relation to distance from high voltage power lines in England and Wales: a case-control study. Bmj. 2005;330(7503):1290.
Sermage-Faure C, Demoury C, Rudant J, Goujon-Bellec S, Guyot-Goubin A, Deschamps F, et al. Childhood leukaemia close to high-voltage power lines–the Geocap study, 2002–2007. British journal of cancer. 2013;108(9):1899-906.
Mahoney MC, Moysich KB, McCarthy PL, McDonald RC, Stepanenko VF, Day RW, et al. The Chernobyl childhood leukemia study: background & lessons learned. Environmental Health. 2004;3(1):1.
Ron E. Ionizing radiation and cancer risk: evidence from epidemiology. Radiation research. 1998;150(5s):S30-S41.
Doll R, Wakeford R. Risk of childhood cancer from fetal irradiation. The British journal of radiology. 1997;70(830):130-9.
Neel JV, Schull WJ. The children of atomic bomb survivors: a genetic study: National Academies Press; 1991.
Boice JD. Cancer following irradiation in childhood and adolescence. Medical and Pediatric Oncology. 1996;27(S1):29-34.
Moysich KB, Menezes RJ, Michalek AM. Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. The Lancet Oncology. 2002;3(5):269-79.
Parkin D, Clayton D, Black R, Masuyer E, Friedl H, Ivanov E, et al. Childhood leukaemia in Europe after Chernobyl: 5 year follow-up. British journal of cancer. 1996;73(8):1006.
Shu XO, Potter JD, Linet MS, Severson RK, Han D, Kersey JH, et al. Diagnostic X-rays and ultrasound exposure and risk of childhood acute lymphoblastic leukemia by immunophenotype. Cancer Epidemiology Biomarkers & Prevention. 2002;11(2):177-85.
Ahlbom A, Day N, Feychting M, Roman E, Skinner J, Dockerty J, et al. A pooled analysis of magnetic fields and childhood leukaemia. British journal of cancer. 2000;83(5):692.
Greenland S, Sheppard AR, Kaune WT, Poole C, Kelsh MA, Group CL-ES. A pooled analysis of magnetic fields, wire codes, and childhood leukemia. Epidemiology. 2000;11(6):624-34.
Infante-Rivard C, Deadman JE. Maternal occupational exposure to extremely low frequency magnetic fields during pregnancy and childhood leukemia. Epidemiology. 2003;14(4):437-41.
Brain JD, Kavet R, McCormick DL, Poole C, Silverman LB, Smith TJ, et al. Childhood leukemia: electric and magnetic fields as possible risk factors. Environmental Health Perspectives. 2003;111(7):962.
Linet MS, Hatch EE, Kleinerman RA, Robison LL, Kaune WT, Friedman DR, et al. Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. New England journal of medicine. 1997;337(1):1-8.
Shu X-O, Ross JA, Pendergrass TW, Reaman GH, Lampkin B, Robison LL. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group study. Journal of the National Cancer Institute. 1996;88(1):24-31.
van Duijn CM, van Steensel-Moll HA, Coebergh J, van Zanen GE. Risk factors for childhood acute non-lymphocytic leukemia: an association with maternal alcohol consumption during pregnancy? Cancer Epidemiology Biomarkers & Prevention. 1994;3(6):457-60.
Brondum J, Shu XO, Steinbuch M, Severson RK, Potter JD, Robison LL. Parental cigarette smoking and the risk of acute leukemia in children. Cancer. 1999;85(6):1380-8.
Robison LL, Buckley JD, Daigle AE, Wells R, Benjamin D, Arthur DC, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer. 1989;63(10):1904-11.
- Abstract Viewed: 574 times
- PDF Downloaded: 333 times